Read by QxMD icon Read

Ocular melanoma

Bella H V Nguyen, James Kuo, Anadian Budiman, Hayden Christie, Sayed Ali
Immune checkpoint inhibitors have changed the landscape of the treatment of multiple solid malignancies, and have been used increasingly in the recent years. Although usually well tolerated, given the relative inexperience of using immune checkpoint inhibitors, we are still learning of new side effects from the treatment. We report on two cases of ocular myasthenia gravis that occurred after treatment with pembrolizumab, an antiprogrammed-death (anti-PD1) monoclonal antibody for advanced melanoma in responding patients...
October 21, 2016: Melanoma Research
Margaret L Pfeiffer, Omar K Ozgur, Jeffrey N Myers, Andrew Peng, Jing Ning, Mark E Zafereo, Sudip Thakar, Bradley Thuro, Victor G Prieto, Merrick I Ross, Bita Esmaeli
BACKGROUND: We sought to update our prior report of findings on sentinel lymph node biopsy (SLNB) and predictors of a positive SLN in patients with conjunctival or eyelid melanoma. METHODS: We reviewed the records of all patients with ocular adnexal melanoma who underwent SLNB at one institution during 2000-2015. We determined rates of positive and false-negative findings on SLNB, primary tumour features correlated with positive findings and rate of nodal recurrence (false-negative event) after negative findings...
October 24, 2016: Acta Ophthalmologica
Pietro Valerio Foti, Antonio Longo, Michele Reibaldi, Andrea Russo, Giuseppe Privitera, Corrado Spatola, Luigi Raffaele, Vincenzo Salamone, Renato Farina, Stefano Palmucci, Andrea Musumeci, Rosario Caltabiano, Marco Ragusa, Cesare Mariotti, Teresio Avitabile, Pietro Milone, Giovanni Carlo Ettorre
PURPOSE: The purpose of this prospective study was to investigate the proton-beam-induced changes in apparent diffusion coefficient (ADC) values of ocular melanoma treated with proton-beam therapy (PBT) in patients undergoing long-term magnetic resonance imaging (MRI) follow-up and to assess whether variations in ADC constitute a reliable biomarker for predicting and detecting the response of ocular melanoma to PBT. METHODS: Seventeen patients with ocular melanoma treated with PBT were enrolled...
October 17, 2016: La Radiologia Medica
S Ajamil Rodanés, C García-Álvarez, M A Saornil Alvarez, F López-Lara, J M Frutos Baraja, M Quiñones
CLINICAL CASE: A 35-year-old male with unilateral ocular hypertension in the right eye (RE). Anterior segment examination of the RE showed a melanotic lesion. Intraocular pressure (IOP) was 40mmHg in RE. Gonioscopy revealed extension into the anterior chamber angle. Excisional biopsy was performed and consistent with iris melanoma and secondary melanomalytic glaucoma. Brachytherapy was performed as adjuvant therapy. DISCUSSION: In patients presenting with unilateral glaucoma and increased pigmentation in the trabecular meshwork, it is crucial to perform imaging studies...
October 13, 2016: Archivos de la Sociedad Española de Oftalmología
Donghyun Lee, Changho Lee, Sehui Kim, Qifa Zhou, Jeehyun Kim, Chulhong Kim
Since its first implementation in otolaryngological surgery nearly a century ago, the surgical microscope has improved the accuracy and the safety of microsurgeries. However, the microscope shows only a magnified surface view of the surgical region. To overcome this limitation, either optical coherence tomography (OCT) or photoacoustic microscopy (PAM) has been independently combined with conventional surgical microscope. Herein, we present a near-infrared virtual intraoperative photoacoustic optical coherence tomography (NIR-VISPAOCT) system that combines both PAM and OCT with a conventional surgical microscope...
October 12, 2016: Scientific Reports
Carol L Shields, Adel E Alset, Nina S Boal, Mairghread G Casey, Austen N Knapp, Jordan A Sugarman, Marisa A Schoen, Phillip S Gordon, Alexzandra M Douglass, Kareem Sioufi, Emil A T Say, Jerry A Shields
PURPOSE: To evaluate frequency of conjunctival tumors in all ages and compare benign versus (vs) malignant counterparts. DESIGN: Retrospective series. METHODS: Setting: Tertiary referral center STUDY POPULATION: 5002 patients OBSERVATION: Clinical features MAIN OUTCOME MEASURE: Differentiation benign from malignant counterparts RESULTS: The tumor was benign (52%), premalignant (18%), or malignant (30%). Malignant tumors included melanoma (12%), squamous cell carcinoma (9%), lymphoma (7%), and others...
October 7, 2016: American Journal of Ophthalmology
Cumhur Selcuk Topal, Gözde Kır, Taner Daş, Billur Sarbay, Muzaffer İlkay Tosun
Metastatic bladder tumors constitute <5% of all bladder tumors and metastatic malignant melanoma of the urinary bladder is very rare. We present a case report of a metastatic malignant melanoma of the urinary bladder. A 70-year-old woman without any apparent significant clinical history was admitted to the Department of Urology for gross hematuria. Microscopic findings of the transurethral resection specimen revealed fascicles, sheets, and diffuse areas composed of oval and fusiform cells with focal pigmentation...
October 2016: Indian Journal of Pathology & Microbiology
Kirollos S Hanna
PURPOSE: Pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, is a humanized monoclonal antibody used in the treatment of metastatic or unresectable melanoma and advanced non-small cell lung cancer (NSCLC). We hereby report a case of pembrolizumab-induced uveitis to increase practitioner awareness. CASE REPORT: A 78-year-old female presented with onset of panuveitis after initiation of pembrolizumab therapy for metastatic melanoma. The patient received three cycles of therapy every 21 days during which her symptoms progressively worsened...
September 26, 2016: Pharmacotherapy
Carl F Blackman
No abstract text is available yet for this article.
October 7, 2016: Electromagnetic Biology and Medicine
Talayesa Buntinx-Krieg, Jie Ouyang, Mont Cartwright
Melanomas arising from orbital melanocytic proliferations are exceedingly rare. Many questions remain regarding their development and malignant transformation. We report on a 45-year-old Caucasian woman with a nevus of Ota that presented with visual disturbances involving her right eye and was found to have a biopsy-proven cellular blue nevus in the orbital space. Five years later, she presented with proptosis and worsening symptoms. Biopsy at that time showed a cellular blue nevus with areas of melanoma. We conclude that patients with a nevus of Ota or an orbital cellular blue nevus, particularly Caucasians, should be monitored for ocular/orbital involvement and followed closely for signs of rapid growth...
July 18, 2016: Curēus
Amra Nadarevic Vodencarevic, Vahid Jusufovic, Svjetlana Terzic, Musfaha Burgic, Meliha Halibasic, Mersiha Sinanovic
AIM: Melanoma represents a malignant tumour arising from melanocytes. Uveal melanoma is the most common primary ocular malignancy among the adult population. The aim of the study was to examine epidemiological characteristics of ocular melanoma in University Clinic Centre in Tuzla, Bosnia and Herzegovina from January 2001 till November 2015. METHODS AND MATERIALS: In this retrospective study we used all available medical documentation to investigate the clinical findings which included age, gender, tumour size, histopathological features and the precise anatomic origin of the ocular melanoma...
July 24, 2016: Materia Socio-medica
Tianzhi Chen, Haidong Wang, Yu Liu, Bingling Zhao, Yuanyuan Zhao, Ruiwen Fan, Pengchao Wang, Changsheng Dong
To investigate whether ocular albinism type 1 (OA1) is differentially expressed in the skin of mice with different coat colors and to determine its correlation with coat color establishment in mouse, the expression patterns and tissue distribution characterization of OA1 in the skin of mice with different coat colors were qualitatively and quantitatively analyzed by real-time quantitative PCR (qRT-PCR), immunofluorescence staining and Western blot. The qRT-PCR analysis revealed that OA1 mRNA was expressed in all mice skin samples tested, with the highest expression level in brown skin, a moderate expression level in black skin and the lowest expression level in gray skin...
2016: International Journal of Molecular Sciences
O F Iskanderani, B N Dominic, R Doucet, G Coulombe, D Pascale, D Roberge
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
L Kropp, C Dulaney, W Gannon, I A Brezovich, J Mason, R Y Kim
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
D Chuard, V Anthonipillai, R Dendale, C Nauraye, E Khan, C Mabit, L De Marzi, L Narici
Particle therapy provides an opportunity to study the human response to space radiation in ground-based facilities. On this basis, a study of light flashes analogous to astronauts' phosphenes reported by patients undergoing ocular proton therapy has been undertaken. The influence of treatment parameters on phosphene generation was investigated for 430 patients treated for a choroidal melanoma at the proton therapy centre of the Institut Curie (ICPO) in Orsay, France, between 2008 and 2011. 60% of them report light flashes, which are predominantly (74%) blue...
August 2016: Life Sciences in Space Research
Michał Romański, Anna Kasprzyk, Agnieszka Karbownik, Franciszek K Główka
Treosulfan (TREO) has an established position in chemotherapy of advanced ovarian cancer but has been also applied in uveal melanoma patients. Moreover, it is used as an orphan drug for a myeloablative conditioning prior to stem cell transplantation. In this paper, biodistribution of prodrug TREO and its active monoepoxide (S,S-EBDM) and diepoxide (S,S-DEB) into aqueous humor of the eye was studied for the first time. For that purpose, alone TREO and the mixture of TREO, S,S-EBDM and S,S-DEB were administered intravenously to New Zealand White rabbits...
October 2016: Drug Metabolism and Pharmacokinetics
Joshua Ford, Bradley A Thuro, Sudip Thakar, Wen-Jen Hwu, Karina Richani, Bita Esmaeli
Programmed cell death 1 (PD-1) inhibitors are members of a new class of drugs known as immune checkpoint inhibitors and have proven efficacy in the treatment of metastatic melanoma. Herein, the authors report the use of nivolumab and pembrolizumab, 2 recently Food and Drug Administration-approved PD-1 inhibitors, in 3 patients: 1 with metastatic conjunctival melanoma and 2 with metastatic cutaneous melanoma and orbital involvement. The patients' metastatic disease responded well to drug treatment. As of this writing, 2 patients have completed therapy and remain disease free at least 1 year after treatment completion; the other patient is still receiving treatment, and his orbital disease is responding...
September 21, 2016: Ophthalmic Plastic and Reconstructive Surgery
Ivana K Kim, Anne Marie Lane, Purva Jain, Caroline Awh, Evangelos S Gragoudas
PURPOSE: To investigate the safety and potential efficacy of ranibizumab for prevention of radiation complications in patients treated with proton irradiation for choroidal melanoma. METHODS: Forty patients with tumors located within 2 disc diameters of the optic nerve and/or macula were enrolled in this open-label study. Participants received ranibizumab 0.5 mg or 1.0 mg at tumor localization and every 2 months thereafter for the study duration of 24 months. The incidence of adverse events, visual acuity, and other measures of ocular morbidity related to radiation complications were assessed...
August 2016: Transactions of the American Ophthalmological Society
J Doyen, P-Y Bondiau, K Benezery, J Thariat, M Vidal, A Gérard, J Hérault, C Carrie, J-M Hannoun-Lévi
Purpose was to summarize results for proton therapy in cancer treatment. A systematic review has been done by selecting studies on the website (Medline) and using the following keywords: proton therapy, radiation therapy, cancer, chordoma, chondrosarcoma, uveal melanoma, retinoblastoma, meningioma, glioma, neurinoma, pituitary adenoma, medulloblastoma, ependymoma, craniopharyngioma and nasal cavity. There are several retrospective studies reporting results for proton therapy in cancer treatments in the following indications: ocular tumors, nasal tumors, skull-based tumors, pediatric tumors...
October 2016: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
Shuo You, Jing Luo, Hans E Grossniklaus, Ma-Ling Gou, Ke Meng, Qing Zhang
Rapid advances in nanomedicine have significantly changed many aspects of nanoparticle application to the eye including areas of diagnosis, imaging and more importantly drug delivery. The nanoparticle-based drug delivery systems has provided a solution to various drug solubility-related problems in ophthalmology treatment. Nanostructured compounds could be used to achieve local ocular delivery with minimal unwanted systematic side effects produced by taking advantage of the phagocyte system. In addition, the in vivo control release by nanomaterials encapsulated drugs provides prolong exposure of the compound in the body...
2016: International Journal of Ophthalmology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"